Company intelligence / Profile preview

siRNAgen Therapeutics

Cambridge, Massachusetts, USsirnagen.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Developing RNAi therapies for chronic inflammatory and CNS conditions using proprietary SAMiRNA™ delivery technology. Lead candidate SRN-001 targets IPF with planned IND submission in late2022[5], though current pipeline shows Phase1 status[4].

Therapeutic areas: DermatologyPulmonologyNeurology
Modalities: RNAisiRNA
Industry: Biotech

Drug pipeline

1 asset

SRN-001

Partnerships

Endless Frontier Labs at NYU Stern (2022 cohort)

Beyond the preview

Go deeper on siRNAgen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNAgen Therapeutics.

Explore the full profile